Monitoring non-small cell lung cancer progression and treatment response through hyaluronic acid in sputum

Autor(es):Mostrar menos -

J. Chinoca ^[1] ; D.S. Andrade ^[2] ; A. Mendes ^[3] ; P. De Marchi ^[4] ; T.G. Prieto ^[5] ; C.M. Baldavira ^[6] ; C. Farhat ^[7] ; J.R.M. Martins ; H.B. Nader ^[9] ; D.M. Carraro ^[10] ; V.L. Capelozzi ^[11] ; V. de Sá

Afiliação do(s) autor(es):Mostrar menos -

^[1] AC Camargo Cancer Center. Laboratório de Genômica e Biologia Molecular - Brasil

^[2] AC Camargo Cancer Center. Laboratório de Genômica e Biologia Molecular - Brasil

^[3] Universidade Federal de São Paulo. Disciplina de Biologia Molecular, Escola Paulista de Medicina. Departamento de Bioquímica - Brasil

^[4] Hospital de Amor de Barretos. Departamento de Oncologia Médica - Brasil

^[5] Universidade de São Paulo. Faculdade de Medicina. Departamento de Patologia - Brasil

^[6] Universidade de São Paulo. Faculdade de Medicina. Departamento de Patologia - Brasil

^[7] Universidade de São Paulo. Faculdade de Medicina. Departamento de Patologia - Brasil

^[9] Universidade Federal de São Paulo. Disciplina de Biologia Molecular, Escola Paulista de Medicina. Departamento de Bioquímica - Brasil

^[10] AC Camargo Cancer Center. Laboratório de Genômica e Biologia Molecular - Brasil

^[11] Universidade de São Paulo. Faculdade de Medicina. Departamento de Patologia - Brasil

• Tipo de documento: Artigo Científico
• Fonte: Brazilian Journal of Medical and Biological Research; v. 55, 2022-01-25.

Resumo

We evaluated whether hyaluronan (HA) levels in the sputum could be used as a noninvasive tool to predict progressive disease and treatment response, as detected in a computed tomography scan in non-small cell lung cancer (NSCLC) patients. Sputum samples were collected from 84 patients with histological confirmation of NSCLC, 33 of which were in early-stage and 51 in advanced-stage disease. Patients received systemic chemotherapy (CT) after surgery (n=36), combined CT and immunotherapy (IO) (n=15), or targeted therapy for driver mutation and disease relapse (N=4). The primary end-point was to compare sputum HA levels in two different concentrations of hypertonic saline solution with overall survival (OS) and the secondary and exploratory end-points were radiologic responses to treatment and patient outcome. Higher concentrations of HA in the sputum were significantly associated to factors related to tumor stage, phenotype, response to treatment, and outcome. In the early stage, patients with lower sputum HA levels before treatment achieved a complete tumor response after systemic CT with better progression-free survival (PFS) than those with high HA levels. We also examined the importance of the sputum HA concentration and tumor response in the 51 patients who developed metastatic disease and received CT+IO. Patients with low levels of sputum HA showed a complete tumor response in the computed tomography scan and stable disease after CT+IO treatment, as well as a better PFS than those receiving CT alone. HA levels in sputum of NSCLC patients may serve as a candidate biomarker to detect progressive disease and monitor treatment response in computed tomography scans. (AU)

• Processo FAPESP: 15/26642-4 - Detecção de ácido hialurônico e mutações em biópsia líquida de escarro como rastreamento de pacientes com câncer de pulmão
• Beneficiário: Vanessa Karen de Sá
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores
• Processo FAPESP: 18/20403-6 - Marcadores biomoleculares de proliferação e remodelamento em doenças respiratórias agudas e crônicas: promissores alvos terapêuticos
• Beneficiário: Vera Luiza Capelozzi
• Modalidade de apoio: Auxílio à Pesquisa - Temático